4.7 Article

Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2022.01.026

关键词

Type I interferon; antiviral immunity; ISGF3; HLH; type II interferon; GAF; STAT2; IRF9

资金

  1. Munich Clinician Scientist Program at LMU
  2. Bubble Foundation
  3. Care-for-Rare Foundation
  4. MRC [MR/N013840/1]
  5. Else Kroner-Fresenius Stiftung (EKFS) [2017_A110]
  6. German Federal Ministry of Education and Research (BMBF) [01GM1910C]
  7. Wellcome Trust [207556/Z/17/Z, 211153/Z/18/Z]
  8. Wellcome Trust [207556/Z/17/Z, 211153/Z/18/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

This study investigated the abnormality of IFN-I signaling in patients with STAT2 and IRF9 deficiency and found that it may contribute to inflammatory responses. IFN-alpha receptor signaling in cells lacking STAT2 or IRF9 was prolonged, and the transcriptional response resembled that of IFN-gamma.
Background: Inflammatory phenomena such as hyperinflammation or hemophagocytic lymphohistiocytosis are a frequent yet paradoxical accompaniment to virus susceptibility in patients with impairment of type I interferon (IFN-I) signaling caused by deficiency of signal transducer and activator of transcription 2 (STAT2) or IFN regulatory factor 9 (IRF9). Objective: We hypothesized that altered and/or prolonged IFN-I signaling contributes to inflammatory complications in these patients. Methods: We explored the signaling kinetics and residual transcriptional responses of IFN-stimulated primary cells from individuals with complete loss of one of STAT1, STAT2, or IRF9 as well as gene-edited induced pluripotent stem cell-derived macrophages. Results: Deficiency of any IFN-stimulated gene factor 3 component suppressed but did not abrogate IFN-I receptor signaling, which was abnormally prolonged, in keeping with insufficient induction of negative regulators such as ubiquitin-specific peptidase 18 (USP18). In cells lacking either STAT2 or IRF9, this late transcriptional response to IFN-alpha 2b mimicked the effect of IFN-gamma. Conclusion: Our data suggest a model wherein the failure of negative feedback of IFN-I signaling in STAT2 and IRF9 deficiency leads to immune dysregulation. Aberrant IFN-alpha receptor signaling in STAT2- and IRF9-deficient cells switches the transcriptional output to a prolonged, IFN-gamma-like response and likely contributes to clinically overt inflammation in these individuals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

Adrian M. Shields, Ariharan Anantharachagan, Gururaj Arumugakani, Kenneth Baker, Sameer Bahal, Helen Baxendale, William Bermingham, Malini Bhole, Evon Boules, Philip Bright, Charu Chopra, Lucy Cliffe, Betsy Cleave, John Dempster, Lisa Devlin, Fatima Dhalla, Lavanya Diwakar, Elizabeth Drewe, Christopher Duncan, Magdalena Dziadzio, Suzanne Elcombe, Shuayb Elkhalifa, Andrew Gennery, Harichandrana Ghanta, Sarah Goddard, Sofia Grigoriadou, Scott Hackett, Grant Hayman, Richard Herriot, Archana Herwadkar, Aarnoud Huissoon, Rashmi Jain, Stephen Jolles, Sarah Johnston, Sujoy Khan, James Laffan, Peter Lane, Lucy Leeman, David M. Lowe, Shanti Mahabir, Dylan James Mac Lochlainn, Elizabeth McDermott, Siraj Misbah, Fiona Moghaddas, Hadeil Morsi, Sai Murng, Sadia Noorani, Rachael O'Brien, Smita Patel, Arthur Price, Tasneem Rahman, Suranjith Seneviratne, Anna Shrimpton, Catherine Stroud, Moira Thomas, Katie Townsend, Prashantha Vaitla, Nisha Verma, Anthony Williams, Siobhan O. Burns, Sinisa Savic, Alex G. Richter

Summary: This study investigates the outcomes of 310 patients with primary or secondary immunodeficiency in the United Kingdom following SARS-CoV-2 infection, and finds significantly elevated mortality rates in both cohorts compared to the general population. Increasing age, pre-existing lymphopenia, and other co-morbidities are identified as additional risk factors for death from COVID-19 in this cohort.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)

Article Medicine, General & Internal

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Guilherme Pessoa-Amorim, Natalie Staplin, Jonathan R. Emberson, Mark Campbell, Enti Spata, Leon Peto, Nigel J. Brunskill, Simon Tiberi, Victor Chew, Thomas Brown, Hasan Tahir, Beate Ebert, David Chadwick, Tony Whitehouse, Rahuldeb Sarkar, Clive Graham, J. Kenneth Baillie, Buddha Basnyat, Maya H. Buch, Lucy C. Chappell, Jeremy Day, Saul N. Faust, Raph L. Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J. Landray

Summary: In patients hospitalized with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.

LANCET (2022)

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart, Robert H. Shaw, Xinxue Liu, Melanie Greenland, Parvinder K. Aley, Nick J. Andrews, J. C. Cameron, Sue Charlton, Elizabeth A. Clutterbuck, Andrea M. Collins, Tom Darton, Tanya Dinesh, Christopher J. A. Duncan, Anna England, Saul N. Faust, Daniela M. Ferreira, Adam Finn, Anna L. Goodman, Christopher A. Green, Bassam Hallis, Paul T. Heath, Helen Hill, Bryn M. Horsington, Teresa Lambe, Rajeka Lazarus, Vincenzo Libri, Patrick J. Lillie, Yama F. Mujadidi, Ruth Payne, Emma L. Plested, Samuel Provstgaard-Morys, Maheshi N. Ramasamy, Mary Ramsay, Robert C. Read, Hannah Robinson, Gavin R. Screaton, Nisha Singh, David P. J. Turner, Paul J. Turner, Iason Vichos, Rachel White, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

Article Urology & Nephrology

Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV

Rachel K. Y. Hung, Elizabeth Binns-Roemer, John W. Booth, Rachel Hilton, Mark Harber, Beatriz Santana-Suarez, Lucy Campbell, Julie Fox, Andrew Ustianowski, Catherine Cosgrove, James E. Burns, Amanda Clarke, David A. Price, David Chadwick, Denis Onyango, Lisa Hamzah, Kate Bramham, Caroline A. Sabin, Cheryl A. Winkler, Frank A. Post

Summary: APOL1 high-risk genotypes are strongly associated with kidney disease in people of African ancestry with HIV and account for approximately half of ESKD cases in this cohort.

KIDNEY INTERNATIONAL REPORTS (2022)

Article Urology & Nephrology

Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV

Rachel K. Y. Hung, Elizabeth Binns-Roemer, John W. Booth, Rachel Hilton, Julie Fox, Fiona Burns, Mark Harber, Andrew Ustianowski, Lisa Hamzah, James E. Burns, Amanda Clarke, David A. Price, Stephen Kegg, Denis Onyango, Beatriz Santana-Suarez, Lucy Campbell, Kate Bramham, Claire C. Sharpe, Caroline A. Sabin, Cheryl A. Winkler, Frank A. Post

Summary: This study investigated the association between sickle cell trait (SCT) and kidney disease in people of African ancestry with HIV in the UK. The results showed that individuals with SCT were more likely to have lower glomerular filtration rate, proteinuria, and albuminuria. These associations were particularly significant in participants with low-risk APOL1 genotypes.

KIDNEY INTERNATIONAL REPORTS (2022)

Article Infectious Diseases

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Adrienn Angyal, Stephanie Longet, Shona C. Moore, Rebecca P. Payne, Adam Harding, Tom Tipton, Patpong Rongkard, Mohammad Ali, Luisa M. Hering, Naomi Meardon, James Austin, Rebecca Brown, Donal Skelly, Natalie Gillson, Sue L. Dobson, Andrew Cross, Gurjinder Sandhar, Jonathan A. Kilby, Jessica K. Tyerman, Alexander R. Nicols, Jarmila S. Spegarova, Hema Mehta, Hailey Hornsby, Rachel Whitham, Christopher P. Conlon, Katie Jeffery, Philip Goulder, John Frater, Christina Dold, Matthew Pace, Ane Ogbe, Helen Brown, M. Azim Ansari, Emily Adland, Anthony Brown, Meera Chand, Adrian Shields, Philippa C. Matthews, Susan Hopkins, Victoria Hall, William James, Sarah L. Rowland-Jones, Paul Klenerman, Susanna Dunachie, Alex Richter, Christopher J. A. Duncan, Eleanor Barnes, Miles Carroll, Lance Turtle, Thushan de Silva

Summary: This study compares immune responses to the BNT162b2 mRNA vaccine in healthcare workers with and without previous SARS-CoV-2 infection. The results show that previously infected individuals have stronger spike-specific T-cell and antibody responses after receiving a single dose of the vaccine compared to SARS-CoV-2-naive individuals. This suggests that a single dose of the BNT162b2 vaccine is likely to provide better protection against SARS-CoV-2 infection in individuals with previous infection.

LANCET MICROBE (2022)

Article Gastroenterology & Hepatology

Chromosomal Numerical Aberrations and Rare Copy Number Variation in Patients with Inflammatory Bowel Disease

Paulina Dirvanskyte, Bhaskar Gurram, Chrissy Bolton, Neil Warner, Kelsey D. J. Jones, Helen R. Griffin, Jason Y. Park, Klaus-Michael Keller, Kimberly C. Gilmour, Sophie Hambleton, Aleixo M. Muise, Christian Wysocki, Holm H. Uhlig

Summary: Turner syndrome is associated with increased susceptibility to intestinal inflammation, while other chromosomal abnormalities' contribution to IBD susceptibility is unclear. Some gene deletions are associated with IBD, but they are also detected in healthy populations, suggesting overestimation of IBD expressivity. The duplication of IL2RA/IL15R loci may contribute to IBD risk.

JOURNAL OF CROHNS & COLITIS (2023)

Article Cell & Tissue Engineering

Conjunctival epithelial cells resist productive SARS-CoV-2 infection

Robert M. Jackson, Catherine F. Hatton, Jarmila Stremenova Spegarova, Maria Georgiou, Joseph Collin, Emily Stephenson, Bernard Verdon, Iram J. Haq, Rafiqul Hussain, Jonathan M. Coxhead, Hardeep-Singh Mudhar, Bart Wagner, Megan Hasoon, Tracey Davey, Paul Rooney, C. M. Anjam Khan, Chris Ward, Malcolm Brodlie, Muzlifah Haniffa, Sophie Hambleton, Lyle Armstrong, Francisco Figueiredo, Rachel Queen, Christopher J. A. Duncan, Majlinda Lako

Summary: Conjunctival epithelial cells, the largest exposed epithelium of the ocular surface tissue, may serve as a potential route for SARS-CoV-2 entry. Through the use of an organotypic model and molecular assays, it was found that although conjunctival cells are susceptible to SARS-CoV-2 infection, productive infection does not occur. Furthermore, the early innate immune response in conjunctival cells is characterized by robust NF-KB activity without activation of antiviral interferon signaling.

STEM CELL REPORTS (2022)

Article Microbiology

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Brian J. Willett, Joe Grove, Oscar A. MacLean, Craig Wilkie, Giuditta De Lorenzo, Wilhelm Furnon, Diego Cantoni, Sam Scott, Nicola Logan, Shirin Ashraf, Maria Manali, Agnieszka Szemiel, Vanessa Cowton, Elen Vink, William T. Harvey, Chris Davis, Patawee Asamaphan, Katherine Smollett, Lily Tong, Richard Orton, Joseph Hughes, Poppy Holland, Vanessa Silva, David J. Pascall, Kathryn Puxty, Ana da Silva Filipe, Gonzalo Yebra, Sharif Shaaban, Matthew T. G. Holden, Rute Maria Pinto, Rory Gunson, Kate Templeton, Pablo R. Murcia, Arvind H. Patel, Paul Klenerman, Susanna Dunachie, John Haughney, David L. Robertson, Massimo Palmarini, Surajit Ray, Emma C. Thomson

Summary: Vaccines based on the spike protein of SARS-CoV-2 are vital in combating COVID-19, but the emergence of the Omicron variant poses a threat to this strategy. Studies have shown that the Omicron variant evades neutralization by sera from individuals vaccinated with different vaccines and reduces real-world vaccine effectiveness, although booster vaccination can partially restore its effectiveness. Additionally, the Omicron variant exhibits distinct cell entry pathways and phenotypes, which may contribute to its rapid global spread and altered pathogenicity.

NATURE MICROBIOLOGY (2022)

Letter Hematology

Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience

Adam Al-Hakim, James A. Poulter, Dina Mahmoud, Ailsa M. S. Rose, Suzanne Elcombe, Helen Lachmann, Catherine Cargo, Christopher J. A. Duncan, Mark Bishton, Venetia Bigley, Anjum Khan, Sinisa Savic

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Infectious Diseases

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

Rajeka Lazarus, Christian Taucher, Claire Brown, Irena Corbic Ramljak, Leon Danon, Katrin Dubischar, Christopher J. A. Duncan, Susanne Eder-Lingelbach, Saul N. Faust, Christopher Green, Karishma Gokani, Romana Hochreiter, Johanna Kellett Wright, Dowan Kwon, Alexander Middleditch, Alasdair P. S. Munro, Kush Naker, Florentina Penciu, David Price, Benedicte Querton, Tawassal Riaz, Amy Ross-Russell, Amada Sanchez-Gonzalez, Hayley Wardle, Sarah Warren, Adam Finn

Summary: This study evaluated the safety and optimal dose of a novel inactivated whole-virus adju-vanted vaccine against SARS-CoV-2. The results showed that the vaccine was well tolerated in all tested dose groups, and no safety concerns were identified. The highest dose group exhibited significantly stronger immunogenicity and was chosen for phase 3 clinical development.

JOURNAL OF INFECTION (2022)

Article Infectious Diseases

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers, David Lowson, Ilse Van Dromme, Johan Vingerhoets, Tobias Kamphuis, Gert Scheper, Javier Ruiz-Guinazu, Saul N. Faust, Christoph D. Spinner, Hanneke Schuitemaker, Johan Van Hoof, Macaya Douoguih, Frank Struyf

Summary: This study investigated the efficacy, safety, and immunogenicity of the Ad26.COV2.S vaccine (Janssen) as primary vaccination plus a booster dose. The results showed that a homologous Ad26.COV2.S booster administered 2 months after primary single-dose vaccination in adults had an acceptable safety profile and was efficacious against moderate to severe-critical COVID-19.

LANCET INFECTIOUS DISEASES (2022)

Article Biochemistry & Molecular Biology

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Alexander J. Mentzer, Daniel O'Connor, Sagida Bibi, Irina L. Chelysheva, Elizabeth A. Clutterbuck, Tesfaye Demissie, Tanya Dinesh, Nick M. Edwards, Sally Felle, Shuo C. Feng, Amy Flaxman, Eleanor Karp-Tatham, Grace Li, Xinxue J. Liu, Natalie Marchevsky, Leila Godfrey, Rebecca K. Makinson, Maireid O. Bull, Jamie N. Fowler, Bana Alamad, Tomas Malinauskas, Amanda Chong, Katherine Sanders, Robert Shaw, Merryn Voysey, Matthew D. Snape, Andrew J. Pollard, Teresa Lambe, Julian C. Knight

Summary: Variation in antibody levels elicited by the COVID-19 vaccine ChAdOx1 nCov-19 is linked to specific major histocompatibility complex class II alleles, providing insight into the breadth of immune response among vaccinated individuals. HLA-DQB1*06 allele is associated with higher levels of anti-RBD antibody and decreased risk of breakthrough infection. These findings have implications for future vaccine design and implementation.

NATURE MEDICINE (2023)

Article Immunology

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naive and SARS-CoV-2 previously-infected individuals

Stephanie Longet, Alexander Hargreaves, Saoirse Healy, Rebecca Brown, Hailey R. Hornsby, Naomi Meardon, Tom Tipton, Eleanor Barnes, Susanna Dunachie, Christopher J. A. Duncan, Paul Klenerman, Alex Richter, Lance Turtle, Thushan I. de Silva, Miles W. Carroll

Summary: Two doses of BNT162b2 mRNA vaccine induce a strong systemic humoral response to SARS-CoV-2, but mucosal immune response is important for defense against airborne transmission. This study characterizes the IgG responses to SARS-CoV-2 and other coronaviruses in oral fluid and plasma samples from UK healthcare workers. It also investigates the impact of previous infection and additional vaccine doses on the immune responses.

FRONTIERS IN IMMUNOLOGY (2022)

暂无数据